Skip to main content
Premium Trial:

Request an Annual Quote

Michael French, Alexander Makarov

Premium
MDRNA, formerly Nastech Pharmaceutical, has appointed Michael French as its CEO.
 
French previously served as senior vice president of corporate development at Sirna Therapeutics. Before that, he was CBO of biotech firm Entelos.
 
He holds an MS in physiology and biophysics from Georgetown University and a BS in aerospace engineering from the United States Military Academy.
 

 
Alexander Makarov, director of global research for life sciences mass spectrometry at Thermo Fisher Scientific, has received the 2008 Distinguished Contribution in Mass Spectrometry Award from the American Society for Mass Spectrometry.
 
Makarov was a research fellow at the University of Warwick, Coventry, UK, and he was a senior scientific researcher at the Russian Academy of Sciences in Moscow.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.